Last reviewed · How we verify
trientine dihydrochloride
Trientine is a copper chelator that binds and removes excess copper from the body, reducing copper-mediated tissue damage.
Trientine is a copper chelator that binds and removes excess copper from the body, reducing copper-mediated tissue damage. Used for Wilson's disease (hepatic and neurological manifestations), Copper toxicity.
At a glance
| Generic name | trientine dihydrochloride |
|---|---|
| Also known as | pegylated liposomal doxorubicin, carboplatin |
| Sponsor | Univar BV |
| Drug class | Copper chelator |
| Target | Copper (Cu2+) |
| Modality | Small molecule |
| Therapeutic area | Metabolic/Genetic Disorders |
| Phase | FDA-approved |
Mechanism of action
Trientine dihydrochloride forms stable complexes with copper ions, facilitating their urinary excretion and reducing free copper levels in tissues. This mechanism is particularly important in Wilson's disease, where defective copper excretion leads to toxic accumulation in the liver, brain, and cornea. By lowering bioavailable copper, trientine prevents progressive neurological, hepatic, and ophthalmologic manifestations.
Approved indications
- Wilson's disease (hepatic and neurological manifestations)
- Copper toxicity
Common side effects
- Iron deficiency anemia
- Systemic lupus erythematosus-like syndrome
- Nausea
- Abdominal pain
- Neurological worsening (initial)
Key clinical trials
- Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. (PHASE3)
- Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
- Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
- Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride (PHASE2)
- Real World Evidence Study in Subjects With Wilson's Disease
- The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy (PHASE2)
- Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). (PHASE1)
- International Wilson's Disease Patient Registry (iWilson Registry)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- trientine dihydrochloride CI brief — competitive landscape report
- trientine dihydrochloride updates RSS · CI watch RSS
- Univar BV portfolio CI